Morepen Laboratories Completes First Phase Of Manufacturing Expansion; Shares Rise 3.14%

Mumbai September, 07: Morepen Laboratories Limited has completed the first phase of its manufacturing capacity expansion programme ahead of the schedule indicated earlier, increasing its installed reactor capacity for API and CDMO operations from 535 KL to 614 KL.

The company disclosed the development under Regulation 30 of the SEBI Listing Regulations, describing the capacity increase as an important step in preparing its manufacturing platform for the next phase of growth.

The additional capacity is expected to support the company’s ongoing scale-up of commercial CDMO supplies while also catering to its existing active pharmaceutical ingredient business and future customer programmes.

The expansion forms part of Morepen Laboratories’ broader strategy to build a larger and scalable manufacturing base while maintaining compliance standards across its API and CDMO operations.

Stock Market Snapshot

The Morepen Laboratories share price was trading at ₹117.31 as of 9:36 AM IST on September 7, 2026, up ₹3.57, or 3.14%, from the previous close of ₹113.74, according to the market data shown.

The stock opened at ₹115.96 and moved higher during early trading, touching a high of ₹118.35. Its low for the session stood at ₹114.56 at the time of the latest update.

The share price movement came as the company announced that the first phase of its manufacturing expansion had been completed ahead of schedule.

Reactor Capacity Increased From 535 KL To 614 KL

The key operational change from the first phase is the increase in installed reactor capacity from 535 KL to 614 KL.

This gives Morepen Laboratories additional manufacturing headroom for both API production and CDMO programmes. The company said the enhanced capacity strengthens its readiness for the planned increase in commercial CDMO supplies.

Completing the phase ahead of schedule also allows the expanded manufacturing infrastructure to become available earlier than previously indicated.

CDMO Business Gets Additional Manufacturing Headroom

Morepen Laboratories is positioning its expanded capacity to support the growing requirements of its CDMO business alongside its established API operations.

CDMO manufacturing involves producing pharmaceutical ingredients and related products for customers under contractual arrangements, making manufacturing capacity and execution capability important parts of the business model.

The additional reactor capacity should give the company more room to handle existing customer programmes and support future requirements without relying solely on its earlier installed base.

Morepen Laboratories Focuses On API And Pharmaceutical Manufacturing

Morepen Laboratories operates in the pharmaceutical manufacturing sector, with businesses spanning APIs and other healthcare-related products.

The company has also been developing its CDMO capabilities as part of its strategy to expand beyond its traditional pharmaceutical manufacturing activities.

The latest capacity addition fits into that broader direction, with the company seeking to build a larger manufacturing platform capable of supporting both established operations and new customer programmes.

Expansion Marks Another Step In Morepen’s Growth Plan

The first phase of the expansion represents a tangible increase in manufacturing capacity rather than simply a planned investment announcement.

By completing the phase ahead of schedule, Morepen Laboratories has moved from the expansion stage into utilisation of the additional capacity for its API and CDMO businesses.

The company said the development supports its objective of building a scalable and globally compliant manufacturing platform focused on longer-term customer relationships and sustained growth.

Conclusion

Morepen Laboratories has completed the first phase of its manufacturing capacity expansion ahead of schedule, increasing installed reactor capacity for API and CDMO operations from 535 KL to 614 KL.

The company expects the additional capacity to support the scale-up of commercial CDMO supplies while continuing to serve its existing API business and future customer programmes.

Meanwhile, the Morepen Laboratories share price was at ₹117.31 as of 9:36 AM IST on September 7, 2026, up 3.14% from the previous close.

Source:

• https://www.nseindia.com/get-quote/equity/MOREPENLAB/Morepen-Laboratories-Limited
• https://nsearchives.nseindia.com/corporate/MOREPENLAB_07092026084840_SEIntimation.pdf